Sugar-lowering drugs for type 2 Diabetes Mellitus and Metabolic Syndrome Review of cassical and new compounds: Part-I
| dc.contributor.author | Vieira, Raquel | |
| dc.contributor.author | Souto, Selma B. | |
| dc.contributor.author | Sánchez-López, E. (Elena) | |
| dc.contributor.author | López-Machado, Ana | |
| dc.contributor.author | Severino, Patrícia | |
| dc.contributor.author | Jose, Sajan | |
| dc.contributor.author | Santini, Antonello | |
| dc.contributor.author | Fortiuna, Ana | |
| dc.contributor.author | García López, María Luisa | |
| dc.contributor.author | Silva, Amélia M. | |
| dc.contributor.author | Souto, Eliana B. | |
| dc.date.accessioned | 2020-06-19T14:32:20Z | |
| dc.date.available | 2020-06-19T14:32:20Z | |
| dc.date.issued | 2019-10-10 | |
| dc.date.updated | 2020-06-19T14:32:20Z | |
| dc.description.abstract | Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, thus being associated with severe adverse effects and leading to an emerging interest in natural compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich compounds) as a novel approach for prevention, management and/or treatment of either non-insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this review, some of these promising glucose-lowering agents will be comprehensively discussed | |
| dc.format.extent | 31 p. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.idgrec | 701302 | |
| dc.identifier.issn | 1424-8247 | |
| dc.identifier.pmid | 31658729 | |
| dc.identifier.uri | https://hdl.handle.net/2445/166338 | |
| dc.language.iso | eng | |
| dc.publisher | MDPI | |
| dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/ph12040152 | |
| dc.relation.ispartof | Pharmaceuticals, 2019, vol. 12, num. 4, p. 152 | |
| dc.relation.uri | https://doi.org/10.3390/ph12040152 | |
| dc.rights | cc-by (c) Vieira, Raquel et al., 2019 | |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | |
| dc.source | Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) | |
| dc.subject.classification | Diabetis no-insulinodependent | |
| dc.subject.classification | Síndrome metabòlica | |
| dc.subject.classification | Fitoteràpia | |
| dc.subject.classification | Farmacologia | |
| dc.subject.classification | Glucèmia | |
| dc.subject.other | Non-insulin-dependent diabetes | |
| dc.subject.other | Metabolic syndrome | |
| dc.subject.other | Phytotherapy | |
| dc.subject.other | Pharmacology | |
| dc.subject.other | Blood sugar | |
| dc.title | Sugar-lowering drugs for type 2 Diabetes Mellitus and Metabolic Syndrome Review of cassical and new compounds: Part-I | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion |
Fitxers
Paquet original
1 - 1 de 1